FDA might approve Mix and Match COVID-19 booster shots


According to a recent report by the Wall Street Journal, the Food and Drug Administration (FDA) is close to allowing Americans to chose a booster shot that could be different from the original shot they could have taken. People familiar with the matter informed the Journal of the same.

One of the sources told the WSJ that the FDA would not recommend any booster shot. People could take a booster shot which is different from the ones that they had originally receive. The mix and match approach could come into effect from this week, by Wednesday evening, according to people familiar with the matter.

One important issue that would be resolved this week, according to a person familiar with the matter was that both Moderna and Johnson & Johnson would get approval for their booster shots.

The New York Times was the first to report that the FDA would allow mixing and matching of booster shots.

Last week, the FDA’s advisory committee was discussing whether booster shots could be mixed and matched. A preliminary study from the National Institutes of Health (NIH), shared on Friday, found that mixing and matching vaccines gave a good immune response. This was seen notably among those who had received the single dose Johnson & Johnson vaccine.

The NIH study tested with 100 micrograms Moderna doses. The study reported that an additional dose of the same vaccine that was used in the primary series resulted in boosting antibody levels 4-to 20 fold. However, when primary vaccines were mixed and matched with booster doses the antibody levels were boosted 6-to 76-fold.

One of the persons also said that regulatory body was still working on the dose of the booster shot. They had not decided whether those who had received a Pfizer or a Johnson & Johnson vaccine should get a 50 or a 100 microgram booster of the Moderna vaccine. However, those who got two doses of the Moderna vaccine would get a 50 microgram booster.


Follow us on Google news for more updates and News

Full Disclaimer



Get the most important breaking news and analyses for Free.

Thank you for subscribing.

Something went wrong.